LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 26

Search options

  1. Article ; Online: Bacterial and viral infections among adults hospitalized with COVID-19, COVID-NET, 14 states, March 2020-April 2022.

    Shah, Melisa M / Patel, Kadam / Milucky, Jennifer / Taylor, Christopher A / Reingold, Arthur / Armistead, Isaac / Meek, James / Anderson, Evan J / Weigel, Andy / Reeg, Libby / Como-Sabetti, Kathryn / Ropp, Susan L / Muse, Alison / Bushey, Sophrena / Shiltz, Eli / Sutton, Melissa / Talbot, H Keipp / Chatelain, Ryan / Havers, Fiona P

    Influenza and other respiratory viruses

    2023  Volume 17, Issue 3, Page(s) e13107

    Abstract: Background: Bacterial and viral infections can occur with SARS-CoV-2 infection, but prevalence, risk factors, and associated clinical outcomes are not fully understood.: Methods: We used the Coronavirus Disease 2019-Associated Hospitalization ... ...

    Abstract Background: Bacterial and viral infections can occur with SARS-CoV-2 infection, but prevalence, risk factors, and associated clinical outcomes are not fully understood.
    Methods: We used the Coronavirus Disease 2019-Associated Hospitalization Surveillance Network (COVID-NET), a population-based surveillance system, to investigate the occurrence of bacterial and viral infections among hospitalized adults with laboratory-confirmed SARS-CoV-2 infection between March 2020 and April 2022. Clinician-driven testing for bacterial pathogens from sputum, deep respiratory, and sterile sites were included. The demographic and clinical features of those with and without bacterial infections were compared. We also describe the prevalence of viral pathogens including respiratory syncytial virus, rhinovirus/enterovirus, influenza, adenovirus, human metapneumovirus, parainfluenza viruses, and non-SARS-CoV-2 endemic coronaviruses.
    Results: Among 36 490 hospitalized adults with COVID-19, 53.3% had bacterial cultures taken within 7 days of admission and 6.0% of these had a clinically relevant bacterial pathogen. After adjustment for demographic factors and co-morbidities, bacterial infections in patients with COVID-19 within 7 days of admission were associated with an adjusted relative risk of death 2.3 times that of patients with negative bacterial testing.
    Conclusions: Among patients with clinician-driven testing, 6.0% of adults hospitalized with COVID-19 were identified to have bacterial coinfections and 0.9% were identified to have viral coinfections; identification of a bacterial coinfection within 7 days of admission was associated with increased mortality.
    MeSH term(s) Adult ; Humans ; Coinfection ; COVID-19 ; Influenza, Human ; SARS-CoV-2 ; Virus Diseases ; Bacterial Infections
    Language English
    Publishing date 2023-03-02
    Publishing country England
    Document type Journal Article ; Research Support, U.S. Gov't, P.H.S.
    ZDB-ID 2274538-5
    ISSN 1750-2659 ; 1750-2640
    ISSN (online) 1750-2659
    ISSN 1750-2640
    DOI 10.1111/irv.13107
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Laboratory-Confirmed COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Omicron BA.2 Variant Predominance - COVID-19-Associated Hospitalization Surveillance Network, 14 States, June 20, 2021-May 31, 2022.

    Havers, Fiona P / Patel, Kadam / Whitaker, Michael / Milucky, Jennifer / Reingold, Arthur / Armistead, Isaac / Meek, James / Anderson, Evan J / Weigel, Andy / Reeg, Libby / Seys, Scott / Ropp, Susan L / Spina, Nancy / Felsen, Christina B / Moran, Nancy E / Sutton, Melissa / Talbot, H Keipp / George, Andrea / Taylor, Christopher A

    MMWR. Morbidity and mortality weekly report

    2022  Volume 71, Issue 34, Page(s) 1085–1091

    Abstract: Beginning the week of March 20–26, 2022, the Omicron BA.2 variant of SARS-CoV-2, the virus that causes COVID-19, became the predominant circulating variant in the United States, accounting for >50% of sequenced isolates.* Data from the COVID-19– ... ...

    Abstract Beginning the week of March 20–26, 2022, the Omicron BA.2 variant of SARS-CoV-2, the virus that causes COVID-19, became the predominant circulating variant in the United States, accounting for >50% of sequenced isolates.* Data from the COVID-19–Associated Hospitalization Surveillance Network (COVID-NET) were analyzed to describe recent COVID-19–associated hospitalization rates among adults aged ≥18 years during the period coinciding with BA.2 predominance (BA.2 period [Omicron BA.2 and BA.2.12.1; March 20–May 31, 2022]). Weekly hospitalization rates (hospitalizations per 100,000 population) among adults aged ≥65 years increased threefold, from 6.9 (week ending April 2, 2022) to 27.6 (week ending May 28, 2022); hospitalization rates in adults aged 18–49 and 50–64 years both increased 1.7-fold during the same time interval. Hospitalization rates among unvaccinated adults were 3.4 times as high as those among vaccinated adults. Among hospitalized nonpregnant patients in this same period, 39.1% had received a primary vaccination series and 1 booster or additional dose; 5.0% had received a primary series and ≥2 boosters or additional doses. All adults should stay up to date† with COVID-19 vaccination, and multiple nonpharmaceutical and medical prevention measures should be used to protect those at high risk for severe COVID-19 illness, irrespective of vaccination status§ (1).
    Beginning the week of March 20–26, 2022, the Omicron BA.2 variant of SARS-CoV-2, the virus that causes COVID-19, became the predominant circulating variant in the United States, accounting for >50% of sequenced isolates.* Data from the COVID-19–Associated Hospitalization Surveillance Network (COVID-NET) were analyzed to describe recent COVID-19–associated hospitalization rates among adults aged ≥18 years during the period coinciding with BA.2 predominance (BA.2 period [Omicron BA.2 and BA.2.12.1; March 20–May 31, 2022]). Weekly hospitalization rates (hospitalizations per 100,000 population) among adults aged ≥65 years increased threefold, from 6.9 (week ending April 2, 2022) to 27.6 (week ending May 28, 2022); hospitalization rates in adults aged 18–49 and 50–64 years both increased 1.7-fold during the same time interval. Hospitalization rates among unvaccinated adults were 3.4 times as high as those among vaccinated adults. Among hospitalized nonpregnant patients in this same period, 39.1% had received a primary vaccination series and 1 booster or additional dose; 5.0% had received a primary series and ≥2 boosters or additional doses. All adults should stay up to date† with COVID-19 vaccination, and multiple nonpharmaceutical and medical prevention measures should be used to protect those at high risk for severe COVID-19 illness, irrespective of vaccination status§ (1).
    MeSH term(s) Adolescent ; Adult ; COVID-19/epidemiology ; COVID-19/therapy ; COVID-19 Vaccines ; Hospitalization ; Humans ; SARS-CoV-2 ; United States/epidemiology ; Vaccination
    Chemical Substances COVID-19 Vaccines
    Language English
    Publishing date 2022-08-26
    Publishing country United States
    Document type Journal Article
    ZDB-ID 412775-4
    ISSN 1545-861X ; 0149-2195
    ISSN (online) 1545-861X
    ISSN 0149-2195
    DOI 10.15585/mmwr.mm7134a3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

    Liang, Jennifer L / Tiwari, Tejpratap / Moro, Pedro / Messonnier, Nancy E / Reingold, Arthur / Sawyer, Mark / Clark, Thomas A

    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports

    2018  Volume 67, Issue 2, Page(s) 1–44

    Abstract: This report compiles and summarizes all recommendations from CDC's Advisory Committee on Immunization Practices (ACIP) regarding prevention and control of tetanus, diphtheria, and pertussis in the United States. As a comprehensive summary of previously ... ...

    Abstract This report compiles and summarizes all recommendations from CDC's Advisory Committee on Immunization Practices (ACIP) regarding prevention and control of tetanus, diphtheria, and pertussis in the United States. As a comprehensive summary of previously published recommendations, this report does not contain any new recommendations and replaces all previously published reports and policy notes; it is intended for use by clinicians and public health providers as a resource. ACIP recommends routine vaccination for tetanus, diphtheria, and pertussis. Infants and young children are recommended to receive a 5-dose series of diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccines, with one adolescent booster dose of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. Adults who have never received Tdap also are recommended to receive a booster dose of Tdap. Women are recommended to receive a dose of Tdap during each pregnancy, which should be administered from 27 through 36 weeks' gestation, regardless of previous receipt of Tdap. After receipt of Tdap, adolescents and adults are recommended to receive a booster tetanus and diphtheria toxoids (Td) vaccine every 10 years to assure ongoing protection against tetanus and diphtheria.
    MeSH term(s) Adolescent ; Adult ; Advisory Committees ; Aged ; Aged, 80 and over ; Centers for Disease Control and Prevention (U.S.) ; Child ; Child, Preschool ; Diphtheria/epidemiology ; Diphtheria/prevention & control ; Diphtheria-Tetanus-Pertussis Vaccine/administration & dosage ; Female ; Humans ; Immunization Schedule ; Immunization, Secondary ; Infant ; Male ; Middle Aged ; Pregnancy ; Tetanus/epidemiology ; Tetanus/prevention & control ; United States/epidemiology ; Vaccination/standards ; Whooping Cough/epidemiology ; Whooping Cough/prevention & control ; Young Adult
    Chemical Substances Diphtheria-Tetanus-Pertussis Vaccine
    Language English
    Publishing date 2018--27
    Publishing country United States
    Document type Journal Article ; Practice Guideline
    ZDB-ID 1020048-4
    ISSN 1545-8601 ; 1057-5987
    ISSN (online) 1545-8601
    ISSN 1057-5987
    DOI 10.15585/mmwr.rr6702a1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Shedding Light on Alopecia Areata in Pediatrics: A Retrospective Analysis of Comorbidities in Children in the National Alopecia Areata Registry.

    Sorrell, Jennifer / Petukhova, Lynn / Reingold, Rachel / Christiano, Angela / Garzon, Maria

    Pediatric dermatology

    2017  Volume 34, Issue 5, Page(s) e271–e272

    Abstract: Alopecia areata (AA) is a common autoimmune disease and it is challenging to predict which patients will have severe disease. The purpose of this retrospective study was to identify comorbidities in children enrolled in the National Alopecia Areata ... ...

    Abstract Alopecia areata (AA) is a common autoimmune disease and it is challenging to predict which patients will have severe disease. The purpose of this retrospective study was to identify comorbidities in children enrolled in the National Alopecia Areata Registry. Atopic dermatitis was more common in patients with severe AA than in those with mild disease. The most common autoimmune comorbidities were vitiligo, psoriasis, thyroid disease, and juvenile idiopathic arthritis.
    Language English
    Publishing date 2017-09
    Publishing country United States
    Document type Journal Article
    ZDB-ID 605539-4
    ISSN 1525-1470 ; 0736-8046
    ISSN (online) 1525-1470
    ISSN 0736-8046
    DOI 10.1111/pde.13238
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Rivastigmine for the treatment of dementia associated with Parkinson's disease.

    Reingold, Jennifer L / Morgan, John C / Sethi, Kapil D

    Neuropsychiatric disease and treatment

    2009  Volume 3, Issue 6, Page(s) 775–783

    Abstract: Parkinson's disease (PD) afflicts millions of people worldwide and leads to cognitive impairment or dementia in the majority of patients over time. Parkinson's disease dementia (PDD) is characterized by deficits in attention, executive and visuospatial ... ...

    Abstract Parkinson's disease (PD) afflicts millions of people worldwide and leads to cognitive impairment or dementia in the majority of patients over time. Parkinson's disease dementia (PDD) is characterized by deficits in attention, executive and visuospatial function, and memory. The clinical diagnostic criteria and neuropathology surrounding PDD remain controversial with evidence of overlap among PDD, dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). Cortical cholinergic deficits are greater in PDD than in AD, and are well-correlated with the cognitive and neuropsychiatric dysfunction that occurs in PDD. Inhibition of acetylcholine metabolism is therefore a practical therapeutic strategy in PDD.This review examines current evidence for rivastigmine (a cholinesterase/butyrylcholinesterase inhibitor) treatment in PDD. In addition to its efficacy, we examine the safety profile, side effects, and cost effectiveness of rivastigmine in PDD. Rivastigmine provides modest benefit in PDD and further long-term studies are needed to determine the effectiveness and safety of rivastigmine over time. Tolerability is a problem for many PDD patients treated with rivastigmine. Future studies of rivastigmine in PDD should focus on pragmatic outcomes such as time to need for nursing home placement, pharmacoeconomic outcomes and simultaneous patient/caregiver quality of life assessments.
    Language English
    Publishing date 2009-03-20
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 2186503-6
    ISSN 1178-2021 ; 1176-6328
    ISSN (online) 1178-2021
    ISSN 1176-6328
    DOI 10.2147/ndt.s1134
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years - COVID-NET, 13 States, February-April 2021.

    Moline, Heidi L / Whitaker, Michael / Deng, Li / Rhodes, Julia C / Milucky, Jennifer / Pham, Huong / Patel, Kadam / Anglin, Onika / Reingold, Arthur / Chai, Shua J / Alden, Nisha B / Kawasaki, Breanna / Meek, James / Yousey-Hindes, Kimberly / Anderson, Evan J / Farley, Monica M / Ryan, Patricia A / Kim, Sue / Nunez, Val Tellez /
    Como-Sabetti, Kathryn / Lynfield, Ruth / Sosin, Daniel M / McMullen, Chelsea / Muse, Alison / Barney, Grant / Bennett, Nancy M / Bushey, Sophrena / Shiltz, Jessica / Sutton, Melissa / Abdullah, Nasreen / Talbot, H Keipp / Schaffner, William / Chatelain, Ryan / Ortega, Jake / Murthy, Bhavini Patel / Zell, Elizabeth / Schrag, Stephanie J / Taylor, Christopher / Shang, Nong / Verani, Jennifer R / Havers, Fiona P

    MMWR. Morbidity and mortality weekly report

    2021  Volume 70, Issue 32, Page(s) 1088–1093

    Abstract: Clinical trials of COVID-19 vaccines currently authorized for emergency use in the United States (Pfizer-BioNTech, Moderna, and Janssen [Johnson & Johnson]) indicate that these vaccines have high efficacy against symptomatic disease, including moderate ... ...

    Abstract Clinical trials of COVID-19 vaccines currently authorized for emergency use in the United States (Pfizer-BioNTech, Moderna, and Janssen [Johnson & Johnson]) indicate that these vaccines have high efficacy against symptomatic disease, including moderate to severe illness (1-3). In addition to clinical trials, real-world assessments of COVID-19 vaccine effectiveness are critical in guiding vaccine policy and building vaccine confidence, particularly among populations at higher risk for more severe illness from COVID-19, including older adults. To determine the real-world effectiveness of the three currently authorized COVID-19 vaccines among persons aged ≥65 years during February 1-April 30, 2021, data on 7,280 patients from the COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) were analyzed with vaccination coverage data from state immunization information systems (IISs) for the COVID-NET catchment area (approximately 4.8 million persons). Among adults aged 65-74 years, effectiveness of full vaccination in preventing COVID-19-associated hospitalization was 96% (95% confidence interval [CI] = 94%-98%) for Pfizer-BioNTech, 96% (95% CI = 95%-98%) for Moderna, and 84% (95% CI = 64%-93%) for Janssen vaccine products. Effectiveness of full vaccination in preventing COVID-19-associated hospitalization among adults aged ≥75 years was 91% (95% CI = 87%-94%) for Pfizer-BioNTech, 96% (95% CI = 93%-98%) for Moderna, and 85% (95% CI = 72%-92%) for Janssen vaccine products. COVID-19 vaccines currently authorized in the United States are highly effective in preventing COVID-19-associated hospitalizations in older adults. In light of real-world data demonstrating high effectiveness of COVID-19 vaccines among older adults, efforts to increase vaccination coverage in this age group are critical to reducing the risk for COVID-19-related hospitalization.
    MeSH term(s) Aged ; COVID-19/epidemiology ; COVID-19/prevention & control ; COVID-19 Vaccines/administration & dosage ; Hospitalization/statistics & numerical data ; Humans ; United States/epidemiology ; Vaccines, Synthetic ; mRNA Vaccines
    Chemical Substances COVID-19 Vaccines ; Vaccines, Synthetic
    Language English
    Publishing date 2021-08-13
    Publishing country United States
    Document type Journal Article
    ZDB-ID 412775-4
    ISSN 1545-861X ; 0149-2195
    ISSN (online) 1545-861X
    ISSN 0149-2195
    DOI 10.15585/mmwr.mm7032e3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: To our readers: Important notice.

    Poland, Gregory A / van Dijk, Nicolette / Altmann, Danny / Borrow, Ray / Hung, Ivan / Ishii, Ken / Jacobsen, Steve / Krammer, Florian / Larson, Heidi / Lua, Linda / Middelberg, Anton / Nelson, Jennifer / Neuzil, Kathy / Nohynek, Hanna / Reingold, Art / van den Hurk, Sylvia / Kennedy, Rick B / Sadarangani, Sapna

    Vaccine

    2020  Volume 38, Issue 35, Page(s) 5563

    Keywords covid19
    Language English
    Publishing date 2020-07-10
    Publishing country Netherlands
    Document type Editorial
    ZDB-ID 605674-x
    ISSN 1873-2518 ; 0264-410X
    ISSN (online) 1873-2518
    ISSN 0264-410X
    DOI 10.1016/j.vaccine.2020.07.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Internationally Acquired Severe Systemic Infections in Febrile Pediatric Travelers Presenting to the Emergency Department.

    Khan, Masrur A / Rosenberg, Michael G / Fein, Daniel M / Quezada, Xavier H / Reingold, Rachel E / Tadros, Farid K / Wolnerman, Yonatan Y / Yao, Jennifer Y / Schneider, Carisa / Meltzer, James A

    Pediatric emergency care

    2020  Volume 37, Issue 12, Page(s) e1315–e1320

    Abstract: ... and alanine aminotransferase level of 30 IU/L or greater (OR, 8.9; 95% CI, 3.1-25.3).: Conclusions ...

    Abstract Objectives: Most children in the United States who visit the emergency department (ED) with fever have minor illnesses not requiring treatment or hospitalization. However, when a child has recently immigrated or traveled abroad, internationally acquired severe systemic infections (ISSIs) must be considered. We sought to describe children who have traveled internationally and present to the ED with a complaint of fever and to determine risk factors associated with ISSIs in these patients.
    Methods: We conducted a retrospective study of children younger than 18 years who presented to 2 pediatric EDs in Bronx, NY (June 2007 to May 2017). Patients were included if they had both fever within 24 hours and international travel within 30 days. We compared groups using bivariate analyses and created a prediction model for ISSIs using multivariable logistic regression.
    Results: Of the 353 children included, 44 (12%) had ISSI: 25 (57%), malaria; 6 (14%), dengue; and 13 (30%), bacteremia. Eight (18%) of those with ISSI presented with fever to another medical provider in the week prior but did not receive bloodwork. Four variables were independently associated with ISSIs: headache (odds ratio [OR], 21.7; 95% confidence interval [CI], 6.8-69.3), travel to Africa or Asia (OR, 18.8; 95% CI, 4.8-73.2), platelets of 150,000/μL or less (OR, 15.1; 95% CI, 4.7-48.6), and alanine aminotransferase level of 30 IU/L or greater (OR, 8.9; 95% CI, 3.1-25.3).
    Conclusions: Children who travel internationally and present with fever upon return are at substantial risk for developing ISSIs. The diagnosis of ISSIs is often overlooked, but certain risk factors have the potential to aid clinicians.
    MeSH term(s) Child ; Emergency Service, Hospital ; Fever/etiology ; Humans ; Malaria/diagnosis ; Malaria/epidemiology ; Retrospective Studies ; Travel ; United States/epidemiology
    Language English
    Publishing date 2020-01-14
    Publishing country United States
    Document type Journal Article
    ZDB-ID 632588-9
    ISSN 1535-1815 ; 0749-5161
    ISSN (online) 1535-1815
    ISSN 0749-5161
    DOI 10.1097/PEC.0000000000002030
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Relationship between neighborhood census-tract level socioeconomic status and respiratory syncytial virus-associated hospitalizations in U.S. adults, 2015-2017.

    Holmen, Jenna E / Kim, Lindsay / Cikesh, Bryanna / Kirley, Pam Daily / Chai, Shua J / Bennett, Nancy M / Felsen, Christina B / Ryan, Patricia / Monroe, Maya / Anderson, Evan J / Openo, Kyle P / Como-Sabetti, Kathryn / Bye, Erica / Talbot, H Keipp / Schaffner, William / Muse, Alison / Barney, Grant R / Whitaker, Michael / Ahern, Jennifer /
    Rowe, Christopher / Langley, Gayle / Reingold, Art

    BMC infectious diseases

    2021  Volume 21, Issue 1, Page(s) 293

    Abstract: Background: Respiratory syncytial virus (RSV) infection causes substantial morbidity and mortality in children and adults. Socioeconomic status (SES) is known to influence many health outcomes, but there have been few studies of the relationship between ...

    Abstract Background: Respiratory syncytial virus (RSV) infection causes substantial morbidity and mortality in children and adults. Socioeconomic status (SES) is known to influence many health outcomes, but there have been few studies of the relationship between RSV-associated illness and SES, particularly in adults. Understanding this association is important in order to identify and address disparities and to prioritize resources for prevention.
    Methods: Adults hospitalized with a laboratory-confirmed RSV infection were identified through population-based surveillance at multiple sites in the U.S. The incidence of RSV-associated hospitalizations was calculated by census-tract (CT) poverty and crowding, adjusted for age. Log binomial regression was used to evaluate the association between Intensive Care Unit (ICU) admission or death and CT poverty and crowding.
    Results: Among the 1713 cases, RSV-associated hospitalization correlated with increased CT level poverty and crowding. The incidence rate of RSV-associated hospitalization was 2.58 (CI 2.23, 2.98) times higher in CTs with the highest as compared to the lowest percentages of individuals living below the poverty level (≥ 20 and < 5%, respectively). The incidence rate of RSV-associated hospitalization was 1.52 (CI 1.33, 1.73) times higher in CTs with the highest as compared to the lowest levels of crowding (≥5 and < 1% of households with > 1 occupant/room, respectively). Neither CT level poverty nor crowding had a correlation with ICU admission or death.
    Conclusions: Poverty and crowding at CT level were associated with increased incidence of RSV-associated hospitalization, but not with more severe RSV disease. Efforts to reduce the incidence of RSV disease should consider SES.
    MeSH term(s) Adolescent ; Adult ; Aged ; Aged, 80 and over ; Censuses ; Female ; Hospitalization/economics ; Hospitalization/statistics & numerical data ; Humans ; Incidence ; Male ; Middle Aged ; Population Surveillance ; Poverty ; Residence Characteristics ; Respiratory Syncytial Virus Infections/economics ; Respiratory Syncytial Virus Infections/epidemiology ; Respiratory Syncytial Virus, Human ; Social Class ; United States/epidemiology ; Young Adult
    Language English
    Publishing date 2021-03-23
    Publishing country England
    Document type Journal Article
    ISSN 1471-2334
    ISSN (online) 1471-2334
    DOI 10.1186/s12879-021-05989-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Census tract socioeconomic indicators and COVID-19-associated hospitalization rates-COVID-NET surveillance areas in 14 states, March 1-April 30, 2020.

    Wortham, Jonathan M / Meador, Seth A / Hadler, James L / Yousey-Hindes, Kimberly / See, Isaac / Whitaker, Michael / O'Halloran, Alissa / Milucky, Jennifer / Chai, Shua J / Reingold, Arthur / Alden, Nisha B / Kawasaki, Breanna / Anderson, Evan J / Openo, Kyle P / Weigel, Andrew / Monroe, Maya L / Ryan, Patricia A / Kim, Sue / Reeg, Libby /
    Lynfield, Ruth / McMahon, Melissa / Sosin, Daniel M / Eisenberg, Nancy / Rowe, Adam / Barney, Grant / Bennett, Nancy M / Bushey, Sophrena / Billing, Laurie M / Shiltz, Jess / Sutton, Melissa / West, Nicole / Talbot, H Keipp / Schaffner, William / McCaffrey, Keegan / Spencer, Melanie / Kambhampati, Anita K / Anglin, Onika / Piasecki, Alexandra M / Holstein, Rachel / Hall, Aron J / Fry, Alicia M / Garg, Shikha / Kim, Lindsay

    PloS one

    2021  Volume 16, Issue 9, Page(s) e0257622

    Abstract: Objectives: Some studies suggested more COVID-19-associated hospitalizations among racial and ethnic minorities. To inform public health practice, the COVID-19-associated Hospitalization Surveillance Network (COVID-NET) quantified associations between ... ...

    Abstract Objectives: Some studies suggested more COVID-19-associated hospitalizations among racial and ethnic minorities. To inform public health practice, the COVID-19-associated Hospitalization Surveillance Network (COVID-NET) quantified associations between race/ethnicity, census tract socioeconomic indicators, and COVID-19-associated hospitalization rates.
    Methods: Using data from COVID-NET population-based surveillance reported during March 1-April 30, 2020 along with socioeconomic and denominator data from the US Census Bureau, we calculated COVID-19-associated hospitalization rates by racial/ethnic and census tract-level socioeconomic strata.
    Results: Among 16,000 COVID-19-associated hospitalizations, 34.8% occurred among non-Hispanic White (White) persons, 36.3% among non-Hispanic Black (Black) persons, and 18.2% among Hispanic or Latino (Hispanic) persons. Age-adjusted COVID-19-associated hospitalization rate were 151.6 (95% Confidence Interval (CI): 147.1-156.1) in census tracts with >15.2%-83.2% of persons living below the federal poverty level (high-poverty census tracts) and 75.5 (95% CI: 72.9-78.1) in census tracts with 0%-4.9% of persons living below the federal poverty level (low-poverty census tracts). Among White, Black, and Hispanic persons living in high-poverty census tracts, age-adjusted hospitalization rates were 120.3 (95% CI: 112.3-128.2), 252.2 (95% CI: 241.4-263.0), and 341.1 (95% CI: 317.3-365.0), respectively, compared with 58.2 (95% CI: 55.4-61.1), 304.0 (95%: 282.4-325.6), and 540.3 (95% CI: 477.0-603.6), respectively, in low-poverty census tracts.
    Conclusions: Overall, COVID-19-associated hospitalization rates were highest in high-poverty census tracts, but rates among Black and Hispanic persons were high regardless of poverty level. Public health practitioners must ensure mitigation measures and vaccination campaigns address needs of racial/ethnic minority groups and people living in high-poverty census tracts.
    MeSH term(s) Adolescent ; Adult ; Aged ; COVID-19/epidemiology ; COVID-19/therapy ; Ethnicity ; Female ; Health Status Disparities ; Hospitalization ; Humans ; Male ; Middle Aged ; Minority Groups ; SARS-CoV-2 ; United States/epidemiology
    Language English
    Publishing date 2021-09-24
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, P.H.S.
    ZDB-ID 2267670-3
    ISSN 1932-6203 ; 1932-6203
    ISSN (online) 1932-6203
    ISSN 1932-6203
    DOI 10.1371/journal.pone.0257622
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top